Anakinra (Raleukin) is an antagonist of recombinant, nonglycosylated human IL-1R. It is the first biological agent to block the pro-inflammatory effects.

Combined etanercept (5 mg/kg, i.p.) and Anakinra (100 mg/kg, I.P. daily for 7 days) substantially improve marginal mass human islet engraftment in immunodeficient mice [2]. Anakinra enhances tumor growth inhibition in mice receiving peptide vaccination and β-(1-3),(1-6)-D-glucan [3].

143090-92-0

C759H1186N208O232S10

17257.6

AMG-719;Anakinra;阿那白滞素

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years